ID   FYN_HUMAN               Reviewed;         537 AA.
AC   P06241; B5BU57; E1P557; H0UI48; Q16248; Q5R3A6; Q5R3A7; Q8N5D7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 222.
DE   RecName: Full=Tyrosine-protein kinase Fyn;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene Syn;
DE   AltName: Full=Proto-oncogene c-Fyn;
DE   AltName: Full=Src-like kinase;
DE            Short=SLK;
DE   AltName: Full=p59-Fyn;
GN   Name=FYN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3099169; DOI=10.1128/MCB.6.12.4195;
RA   Kawakami T., Pennington C.Y., Robbins K.C.;
RT   "Isolation and oncogenic potential of a novel human src-like gene.";
RL   Mol. Cell. Biol. 6:4195-4201(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=3526330; DOI=10.1073/pnas.83.15.5459;
RA   Semba K., Nishizawa M., Miyajima N., Yoshida M.C., Sukegawa J.,
RA   Yamanashi Y., Sasaki M., Yamamoto T., Toyoshima K.;
RT   "Yes-related protooncogene, syn, belongs to the protein-tyrosine
RT   kinase family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5459-5463(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.
RC   TISSUE=T-cell;
RX   PubMed=7822789;
RA   Rigley K., Slocombe P., Proudfoot K., Wahid S., Mandair K.,
RA   Bebbington C.;
RT   "Human p59fyn(T) regulates OKT3-induced calcium influx by a mechanism
RT   distinct from PIP2 hydrolysis in Jurkat T cells.";
RL   J. Immunol. 154:1136-1145(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   MYRISTOYLATION AT GLY-2, AND PHOSPHORYLATION AT TYR-531.
RX   PubMed=1699196;
RA   Peters D.J., McGrew B.R., Perron D.C., Liptak L.M., Laudano A.P.;
RT   "In vivo phosphorylation and membrane association of the fyn proto-
RT   oncogene product in IM-9 human lymphoblasts.";
RL   Oncogene 5:1313-1319(1990).
RN   [9]
RP   DEPHOSPHORYLATION AT TYR-531 BY PTPRC.
RX   PubMed=1533589; DOI=10.1002/eji.1830220510;
RA   Mustelin T., Pessa-Morikawa T., Autero M., Gassmann M.,
RA   Andersson L.C., Gahmberg C.G., Burn P.;
RT   "Regulation of the p59fyn protein tyrosine kinase by the CD45
RT   phosphotyrosine phosphatase.";
RL   Eur. J. Immunol. 22:1173-1178(1992).
RN   [10]
RP   INTERACTION WITH PIK3R1.
RX   PubMed=8394019; DOI=10.1073/pnas.90.15.7366;
RA   Prasad K.V., Janssen O., Kapeller R., Raab M., Cantley L.C.,
RA   Rudd C.E.;
RT   "Src-homology 3 domain of protein kinase p59fyn mediates binding to
RT   phosphatidylinositol 3-kinase in T cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7366-7370(1993).
RN   [11]
RP   PALMITOYLATION.
RX   PubMed=8206991;
RA   Alland L., Peseckis S.M., Atherton R.E., Berthiaume L., Resh M.D.;
RT   "Dual myristylation and palmitylation of Src family member p59fyn
RT   affects subcellular localization.";
RL   J. Biol. Chem. 269:16701-16705(1994).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CD28.
RX   PubMed=7568038; DOI=10.1073/pnas.92.19.8891;
RA   Raab M., Cai Y.C., Bunnell S.C., Heyeck S.D., Berg L.J., Rudd C.E.;
RT   "p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-
RT   kinase, growth factor receptor-bound protein GRB-2, and T cell-
RT   specific protein-tyrosine kinase ITK: implications for T-cell
RT   costimulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:8891-8895(1995).
RN   [13]
RP   INTERACTION WITH KIT.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [14]
RP   INTERACTION WITH FYB.
RC   TISSUE=Tonsil;
RX   PubMed=9207119; DOI=10.1073/pnas.94.14.7493;
RA   da Silva A.J., Li Z., de Vera C., Canto E., Findell P., Rudd C.E.;
RT   "Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-
RT   containing leukocyte protein 76 and modulates interleukin 2
RT   production.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7493-7498(1997).
RN   [15]
RP   INTERACTION WITH CAV1.
RX   PubMed=9741627; DOI=10.1016/S0092-8674(00)81604-9;
RA   Wary K.K., Mariotti A., Zurzolo C., Giancotti F.G.;
RT   "A requirement for caveolin-1 and associated kinase Fyn in integrin
RT   signaling and anchorage-dependent cell growth.";
RL   Cell 94:625-634(1998).
RN   [16]
RP   TISSUE SPECIFICITY, PHOSPHORYLATION, AND ALTERNATIVE SPLICING.
RX   PubMed=10196263;
RA   Weil R., Levraud J.P., Dodon M.D., Bessia C., Hazan U., Kourilsky P.,
RA   Israel A.;
RT   "Altered expression of tyrosine kinases of the Src and Syk families in
RT   human T-cell leukemia virus type 1-infected T-cell lines.";
RL   J. Virol. 73:3709-3717(1999).
RN   [17]
RP   INTERACTION WITH EPHA8.
RX   PubMed=10498895; DOI=10.1038/sj.onc.1202917;
RA   Choi S., Park S.;
RT   "Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates
RT   Fyn binding to the Tyr-615 site by enhancing tyrosine kinase
RT   activity.";
RL   Oncogene 18:5413-5422(1999).
RN   [18]
RP   INTERACTION WITH PAG1.
RX   PubMed=10790433; DOI=10.1084/jem.191.9.1591;
RA   Brdicka T., Pavlistova D., Bruyns E., Leo A., Korinek V.,
RA   Angelisova P., Scherer J., Shevchenko A., Shevchenko A., Hilgert I.,
RA   Cerny J., Drbal K., Kuramitsu Y., Horejsi V., Schraven B.;
RT   "Phosphoprotein associated with glycosphingolipid-enriched
RT   microdomains (PAG), a novel ubiquitously expressed transmembrane
RT   adaptor protein, binds the protein tyrosine kinase csk and is involved
RT   in regulation of T cell activation.";
RL   J. Exp. Med. 191:1591-1604(2000).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF VAV1.
RX   PubMed=11005864; DOI=10.1073/pnas.97.20.10923;
RA   Huang J., Tilly D., Altman A., Sugie K., Grey H.M.;
RT   "T-cell receptor antagonists induce Vav phosphorylation by selective
RT   activation of Fyn kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:10923-10929(2000).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF SNCA.
RX   PubMed=11162638; DOI=10.1006/bbrc.2000.4253;
RA   Nakamura T., Yamashita H., Takahashi T., Nakamura S.;
RT   "Activated Fyn phosphorylates alpha-synuclein at tyrosine residue
RT   125.";
RL   Biochem. Biophys. Res. Commun. 280:1085-1092(2001).
RN   [21]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [22]
RP   FUNCTION.
RX   PubMed=11536198; DOI=10.1002/neu.1066;
RA   Wolf R.M., Wilkes J.J., Chao M.V., Resh M.D.;
RT   "Tyrosine phosphorylation of p190 RhoGAP by Fyn regulates
RT   oligodendrocyte differentiation.";
RL   J. Neurobiol. 49:62-78(2001).
RN   [23]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12218089; DOI=10.4049/jimmunol.169.6.2813;
RA   Yasuda K., Nagafuku M., Shima T., Okada M., Yagi T., Yamada T.,
RA   Minaki Y., Kato A., Tani-Ichi S., Hamaoka T., Kosugi A.;
RT   "Fyn is essential for tyrosine phosphorylation of Csk-binding
RT   protein/phosphoprotein associated with glycolipid-enriched
RT   microdomains in lipid rafts in resting T cells.";
RL   J. Immunol. 169:2813-2817(2002).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF ARHGAP32.
RX   PubMed=12788081; DOI=10.1016/S0006-291X(03)00923-9;
RA   Taniguchi S., Liu H., Nakazawa T., Yokoyama K., Tezuka T.,
RA   Yamamoto T.;
RT   "p250GAP, a neural RhoGAP protein, is associated with and
RT   phosphorylated by Fyn.";
RL   Biochem. Biophys. Res. Commun. 306:151-155(2003).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF TRPC6.
RX   PubMed=14761972; DOI=10.1074/jbc.M311274200;
RA   Hisatsune C., Kuroda Y., Nakamura K., Inoue T., Nakamura T.,
RA   Michikawa T., Mizutani A., Mikoshiba K.;
RT   "Regulation of TRPC6 channel activity by tyrosine phosphorylation.";
RL   J. Biol. Chem. 279:18887-18894(2004).
RN   [26]
RP   FUNCTION.
RX   PubMed=15557120; DOI=10.1083/jcb.200405053;
RA   Meriane M., Tcherkezian J., Webber C.A., Danek E.I., Triki I.,
RA   McFarlane S., Bloch-Gallego E., Lamarche-Vane N.;
RT   "Phosphorylation of DCC by Fyn mediates Netrin-1 signaling in growth
RT   cone guidance.";
RL   J. Cell Biol. 167:687-698(2004).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF WAS.
RX   PubMed=14707117; DOI=10.1084/jem.20030976;
RA   Badour K., Zhang J., Shi F., Leng Y., Collins M., Siminovitch K.A.;
RT   "Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome
RT   protein (WASp) tyrosine phosphorylation is required for coupling T
RT   cell antigen receptor engagement to WASp effector function and T cell
RT   activation.";
RL   J. Exp. Med. 199:99-112(2004).
RN   [28]
RP   INTERACTION WITH UNC119.
RX   PubMed=14757743; DOI=10.1084/jem.20030589;
RA   Gorska M.M., Stafford S.J., Cen O., Sur S., Alam R.;
RT   "Unc119, a novel activator of Lck/Fyn, is essential for T cell
RT   activation.";
RL   J. Exp. Med. 199:369-379(2004).
RN   [29]
RP   REVIEW ON FUNCTION.
RX   PubMed=15489916; DOI=10.1038/sj.onc.1208074;
RA   Palacios E.H., Weiss A.;
RT   "Function of the Src-family kinases, Lck and Fyn, in T-cell
RT   development and activation.";
RL   Oncogene 23:7990-8000(2004).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF MAP2.
RX   PubMed=15536091; DOI=10.1074/jbc.M411380200;
RA   Zamora-Leon S.P., Bresnick A., Backer J.M., Shafit-Zagardo B.;
RT   "Fyn phosphorylates human MAP-2c on tyrosine 67.";
RL   J. Biol. Chem. 280:1962-1970(2005).
RN   [31]
RP   PHOSPHORYLATION AT THR-12, AND SUBCELLULAR LOCATION.
RX   PubMed=15537652; DOI=10.1074/jbc.M402053200;
RA   He Z., Cho Y.Y., Ma W.Y., Choi H.S., Bode A.M., Dong Z.;
RT   "Regulation of ultraviolet B-induced phosphorylation of histone H3 at
RT   serine 10 by Fyn kinase.";
RL   J. Biol. Chem. 280:2446-2454(2005).
RN   [32]
RP   INTERACTION WITH ITCH, AND FUNCTION.
RX   PubMed=16387660; DOI=10.1016/j.molcel.2005.11.014;
RA   Yang C., Zhou W., Jeon M.S., Demydenko D., Harada Y., Zhou H.,
RA   Liu Y.C.;
RT   "Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated
RT   tyrosine phosphorylation.";
RL   Mol. Cell 21:135-141(2006).
RN   [33]
RP   FUNCTION IN PHOSPHORYLATION OF AGAP2.
RX   PubMed=16841086; DOI=10.1038/sj.cdd.4402011;
RA   Tang X., Feng Y., Ye K.;
RT   "Src-family tyrosine kinase fyn phosphorylates phosphatidylinositol 3-
RT   kinase enhancer-activating Akt, preventing its apoptotic cleavage and
RT   promoting cell survival.";
RL   Cell Death Differ. 14:368-377(2007).
RN   [34]
RP   INTERACTION WITH PRMT8.
RX   PubMed=17925405; DOI=10.1074/jbc.M704650200;
RA   Sayegh J., Webb K., Cheng D., Bedford M.T., Clarke S.G.;
RT   "Regulation of protein arginine methyltransferase 8 (PRMT8) activity
RT   by its N-terminal domain.";
RL   J. Biol. Chem. 282:36444-36453(2007).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF CTNND1.
RX   PubMed=17194753; DOI=10.1128/MCB.01974-06;
RA   Castano J., Solanas G., Casagolda D., Raurell I., Villagrasa P.,
RA   Bustelo X.R., Garcia de Herreros A., Dunach M.;
RT   "Specific phosphorylation of p120-catenin regulatory domain
RT   differently modulates its binding to RhoA.";
RL   Mol. Cell. Biol. 27:1745-1757(2007).
RN   [36]
RP   FUNCTION IN PHOSPHORYLATION OF PAG1.
RX   PubMed=18056706; DOI=10.1074/jbc.M705215200;
RA   Solheim S.A., Torgersen K.M., Tasken K., Berge T.;
RT   "Regulation of FynT function by dual domain docking on PAG/Cbp.";
RL   J. Biol. Chem. 283:2773-2783(2008).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF KIRREL.
RX   PubMed=18258597; DOI=10.1074/jbc.M707247200;
RA   Harita Y., Kurihara H., Kosako H., Tezuka T., Sekine T., Igarashi T.,
RA   Hattori S.;
RT   "Neph1, a component of the kidney slit diaphragm, is tyrosine-
RT   phosphorylated by the Src family tyrosine kinase and modulates
RT   intracellular signaling by binding to Grb2.";
RL   J. Biol. Chem. 283:9177-9186(2008).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND TYR-531, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [41]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL
RT   (CD178) by phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [42]
RP   FUNCTION IN PHOSPHORYLATION OF NPHS1.
RX   PubMed=19179337; DOI=10.1074/jbc.M806851200;
RA   Harita Y., Kurihara H., Kosako H., Tezuka T., Sekine T., Igarashi T.,
RA   Ohsawa I., Ohta S., Hattori S.;
RT   "Phosphorylation of nephrin triggers Ca2+ signaling by recruitment and
RT   activation of phospholipase C-{gamma}1.";
RL   J. Biol. Chem. 284:8951-8962(2009).
RN   [43]
RP   FUNCTION IN PHOSPHORYLATION OF DPYSL2.
RX   PubMed=19652227; DOI=10.1074/jbc.M109.000240;
RA   Uchida Y., Ohshima T., Yamashita N., Ogawara M., Sasaki Y.,
RA   Nakamura F., Goshima Y.;
RT   "Semaphorin3A signaling mediated by Fyn-dependent tyrosine
RT   phosphorylation of collapsin response mediator protein 2 at tyrosine
RT   32.";
RL   J. Biol. Chem. 284:27393-27401(2009).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH RUNX3.
RX   PubMed=20100835; DOI=10.1074/jbc.M109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W.,
RA   Li Y.H., Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes
RT   the protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [47]
RP   FUNCTION IN TCR SIGNALING, PHOSPHORYLATION, AND DEPHOSPHORYLATION AT
RP   TYR-420 BY PTPN2.
RX   PubMed=22080863; DOI=10.1172/JCI59492;
RA   Wiede F., Shields B.J., Chew S.H., Kyparissoudis K., van Vliet C.,
RA   Galic S., Tremblay M.L., Russell S.M., Godfrey D.I., Tiganis T.;
RT   "T cell protein tyrosine phosphatase attenuates T cell signaling to
RT   maintain tolerance in mice.";
RL   J. Clin. Invest. 121:4758-4774(2011).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND SER-26, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [49]
RP   INTERACTION WITH ARAP AND FYB.
RX   PubMed=27335501; DOI=10.4049/jimmunol.1501913;
RA   Jung S.H., Yoo E.H., Yu M.J., Song H.M., Kang H.Y., Cho J.Y.,
RA   Lee J.R.;
RT   "ARAP, a novel adaptor protein, is required for TCR signaling and
RT   integrin-mediated adhesion.";
RL   J. Immunol. 197:942-952(2016).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF SH3 DOMAIN.
RX   PubMed=7687536;
RA   Noble M.E.M., Musacchio A., Saraste M., Courtneidge S.A.,
RA   Wierenga R.K.;
RT   "Crystal structure of the SH3 domain in human Fyn; comparison of the
RT   three-dimensional structures of SH3 domains in tyrosine kinases and
RT   spectrin.";
RL   EMBO J. 12:2617-2624(1993).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 81-142.
RX   PubMed=7664083; DOI=10.1038/nsb0894-546;
RA   Musacchio A., Saraste M., Wilmanns M.;
RT   "High-resolution crystal structures of tyrosine kinase SH3 domains
RT   complexed with proline-rich peptides.";
RL   Nat. Struct. Biol. 1:546-551(1994).
RN   [52]
RP   STRUCTURE BY NMR.
RX   PubMed=8961927; DOI=10.1021/bi9620969;
RA   Renzoni D.A., Pugh D.J., Siligardi G., Das P., Morton C.J., Rossi C.,
RA   Waterfield M.D., Campbell I.D., Ladbury J.E.;
RT   "Structural and thermodynamic characterization of the interaction of
RT   the SH3 domain from Fyn with the proline-rich binding site on the p85
RT   subunit of PI3-kinase.";
RL   Biochemistry 35:15646-15653(1996).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 85-141 IN COMPLEX WITH NEF.
RX   PubMed=8681387; DOI=10.1016/S0092-8674(00)81276-3;
RA   Lee C.H., Saksela K., Mirza U.A., Chait B.T., Kuriyan J.;
RT   "Crystal structure of the conserved core of HIV-1 Nef complexed with a
RT   Src family SH3 domain.";
RL   Cell 85:931-942(1996).
RN   [54]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=8805554; DOI=10.1016/S0969-2126(96)00076-7;
RA   Morton C.J., Pugh D.J.R., Brown E.L.J., Kahmann J.D., Renzoni D.A.C.,
RA   Campbell I.D.;
RT   "Solution structure and peptide binding of the SH3 domain from human
RT   Fyn.";
RL   Structure 4:705-714(1996).
RN   [55]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   PubMed=9351806; DOI=10.1016/S0969-2126(97)00283-9;
RA   Mulhern T.D., Shaw G.L., Morton C.J., Day A.J., Campbell I.D.;
RT   "The SH2 domain from the tyrosine kinase Fyn in complex with a
RT   phosphotyrosyl peptide reveals insights into domain stability and
RT   binding specificity.";
RL   Structure 5:1313-1323(1997).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 84-144 IN COMPLEX WITH SLAMF1
RP   AND SH2D1A.
RX   PubMed=12545174; DOI=10.1038/ncb920;
RA   Chan B., Lanyi A., Song H.K., Griesbach J., Simarro-Grande M., Poy F.,
RA   Howie D., Sumegi J., Terhorst C., Eck M.J.;
RT   "SAP couples Fyn to SLAM immune receptors.";
RL   Nat. Cell Biol. 5:155-160(2003).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-243; ARG-410 AND GLU-506.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays a role
CC       in many biological processes including regulation of cell growth
CC       and survival, cell adhesion, integrin-mediated signaling,
CC       cytoskeletal remodeling, cell motility, immune response and axon
CC       guidance. Inactive FYN is phosphorylated on its C-terminal tail
CC       within the catalytic domain. Following activation by PKA, the
CC       protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1
CC       phosphorylation, activation and targeting to focal adhesions.
CC       Involved in the regulation of cell adhesion and motility through
CC       phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-
CC       catenin). Regulates cytoskeletal remodeling by phosphorylating
CC       several proteins including the actin regulator WAS and the
CC       microtubule-associated proteins MAP2 and MAPT. Promotes cell
CC       survival by phosphorylating AGAP2/PIKE-A and preventing its
CC       apoptotic cleavage. Participates in signal transduction pathways
CC       that regulate the integrity of the glomerular slit diaphragm (an
CC       essential part of the glomerular filter of the kidney) by
CC       phosphorylating several slit diaphragm components including NPHS1,
CC       KIRREL and TRPC6. Plays a role in neural processes by
CC       phosphorylating DPYSL2, a multifunctional adapter protein within
CC       the central nervous system, ARHGAP32, a regulator for Rho family
CC       GTPases implicated in various neural functions, and SNCA, a small
CC       pre-synaptic protein. Participates in the downstream signaling
CC       pathways that lead to T-cell differentiation and proliferation
CC       following T-cell receptor (TCR) stimulation. Also participates in
CC       negative feedback regulation of TCR signaling through
CC       phosphorylation of PAG1, thereby promoting interaction between
CC       PAG1 and CSK and recruitment of CSK to lipid rafts. CSK maintains
CC       LCK and FYN in an inactive form. Promotes CD28-induced
CC       phosphorylation of VAV1. {ECO:0000269|PubMed:11005864,
CC       ECO:0000269|PubMed:11162638, ECO:0000269|PubMed:11536198,
CC       ECO:0000269|PubMed:12788081, ECO:0000269|PubMed:14707117,
CC       ECO:0000269|PubMed:14761972, ECO:0000269|PubMed:15536091,
CC       ECO:0000269|PubMed:15557120, ECO:0000269|PubMed:16387660,
CC       ECO:0000269|PubMed:16841086, ECO:0000269|PubMed:17194753,
CC       ECO:0000269|PubMed:18056706, ECO:0000269|PubMed:18258597,
CC       ECO:0000269|PubMed:19179337, ECO:0000269|PubMed:19652227,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:22080863,
CC       ECO:0000269|PubMed:7568038, ECO:0000269|PubMed:7822789}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- ENZYME REGULATION: Inhibited by phosphorylation of Tyr-531 by
CC       leukocyte common antigen and activated by dephosphorylation of
CC       this site.
CC   -!- SUBUNIT: Interacts (via its SH3 domain) with PIK3R1 and PRMT8.
CC       Interacts with FYB, PAG1, and SH2D1A. Interacts with CD79A
CC       (tyrosine-phosphorylated form); the interaction increases FYN
CC       activity. Interacts (via SH2 domain) with CSF1R (tyrosine
CC       phosphorylated) (By similarity). Interacts with TOM1L1
CC       (phosphorylated form). Interacts with KDR (tyrosine
CC       phosphorylated). Interacts (via SH3 domain) with KLHL2 (via N-
CC       terminus) (By similarity). Interacts with SH2D1A and SLAMF1.
CC       Interacts (via its SH3 domain) with HEV ORF3 protein. Interacts
CC       with ITCH; the interaction phosphorylates ITCH and negatively
CC       regulates its activity. Interacts with FASLG. Interacts with
CC       RUNX3. Interacts with KIT. Interacts with EPHA8; possible
CC       downstream effector of EPHA8 in regulation of cell adhesion.
CC       Interacts with PTK2/FAK1; this interaction leads to PTK2/FAK1
CC       phosphorylation and activation. Interacts with CAV1; this
CC       interaction couples integrins to the Ras-ERK pathway. Interacts
CC       with UNC119. Interacts (via SH2 domain) with PTPRH (phosphorylated
CC       form) (By similarity). Interacts with PTPRO (phosphorylated form)
CC       (By similarity). Interacts with PTPRB (phosphorylated form) (By
CC       similarity). Interacts with ARAP (PubMed:27335501).
CC       {ECO:0000250|UniProtKB:P39688, ECO:0000250|UniProtKB:Q62844,
CC       ECO:0000269|PubMed:10498895, ECO:0000269|PubMed:10790433,
CC       ECO:0000269|PubMed:11518702, ECO:0000269|PubMed:12545174,
CC       ECO:0000269|PubMed:14757743, ECO:0000269|PubMed:16387660,
CC       ECO:0000269|PubMed:17925405, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:27335501,
CC       ECO:0000269|PubMed:8394019, ECO:0000269|PubMed:8681387,
CC       ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9207119,
CC       ECO:0000269|PubMed:9741627}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-515315, EBI-515315;
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-515315, EBI-710506;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-515315, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=2; IntAct=EBI-515315, EBI-710918;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-515315, EBI-1102694;
CC       Q13444:ADAM15; NbExp=2; IntAct=EBI-515315, EBI-77818;
CC       A7KAX9:ARHGAP32; NbExp=4; IntAct=EBI-515315, EBI-308663;
CC       O14559:ARHGAP33; NbExp=2; IntAct=EBI-515315, EBI-1210010;
CC       Q9ULH1:ASAP1; NbExp=3; IntAct=EBI-515315, EBI-346622;
CC       P56945:BCAR1; NbExp=3; IntAct=EBI-515315, EBI-702093;
CC       Q13191:CBLB; NbExp=3; IntAct=EBI-10691738, EBI-744027;
CC       O43281:EFS; NbExp=3; IntAct=EBI-515315, EBI-718488;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-515315, EBI-641062;
CC       P48023:FASLG; NbExp=2; IntAct=EBI-515315, EBI-495538;
CC       P02751-7:FN1; NbExp=2; IntAct=EBI-515315, EBI-7133890;
CC       O15117:FYB; NbExp=4; IntAct=EBI-515315, EBI-1753267;
CC       P31424-2:Grm5 (xeno); NbExp=2; IntAct=EBI-515315, EBI-8830305;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-515315, EBI-352572;
CC       P50406:HTR6; NbExp=7; IntAct=EBI-515315, EBI-1182222;
CC       Q07666:KHDRBS1; NbExp=4; IntAct=EBI-515315, EBI-1364;
CC       Q92918:MAP4K1; NbExp=2; IntAct=EBI-515315, EBI-881;
CC       Q9H204:MED28; NbExp=6; IntAct=EBI-515315, EBI-514199;
CC       Q9NZQ3:NCKIPSD; NbExp=2; IntAct=EBI-515315, EBI-745080;
CC       Q8WX92:NELFB; NbExp=2; IntAct=EBI-515315, EBI-347721;
CC       Q9NWQ8:PAG1; NbExp=5; IntAct=EBI-515315, EBI-2828115;
CC       Q8WUM4:PDCD6IP; NbExp=6; IntAct=EBI-515315, EBI-310624;
CC       P09619:PDGFRB; NbExp=3; IntAct=EBI-515315, EBI-641237;
CC       O43900:PRICKLE3; NbExp=2; IntAct=EBI-515315, EBI-1751761;
CC       Q05655:PRKCD; NbExp=5; IntAct=EBI-515315, EBI-704279;
CC       Q04759:PRKCQ; NbExp=7; IntAct=EBI-515315, EBI-374762;
CC       Q13905:RAPGEF1; NbExp=2; IntAct=EBI-515315, EBI-976876;
CC       O60880:SH2D1A; NbExp=3; IntAct=EBI-515315, EBI-6983382;
CC       Q8BHK6:Slamf7 (xeno); NbExp=2; IntAct=EBI-515315, EBI-11463802;
CC       Q9Y2W2:WBP11; NbExp=3; IntAct=EBI-515315, EBI-714455;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.
CC       Note=Present and active in lipid rafts. Palmitoylation is crucial
CC       for proper trafficking.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=B;
CC         IsoId=P06241-1; Sequence=Displayed;
CC       Name=2; Synonyms=T;
CC         IsoId=P06241-2; Sequence=VSP_024110;
CC       Name=3;
CC         IsoId=P06241-3; Sequence=VSP_024108;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is highly expressed in the brain.
CC       Isoform 2 is expressed in cells of hemopoietic lineages,
CC       especially T-lymphocytes. {ECO:0000269|PubMed:10196263}.
CC   -!- PTM: Autophosphorylated at Tyr-420. Phosphorylation on the C-
CC       terminal tail at Tyr-531 by CSK maintains the enzyme in an
CC       inactive state (By similarity). PTPRC/CD45 dephosphorylates Tyr-
CC       531 leading to activation. Ultraviolet B (UVB) strongly increase
CC       phosphorylation at Thr-12 and kinase activity, and promotes
CC       translocation from the cytoplasm to the nucleus. Dephosphorylation
CC       at Tyr-420 by PTPN2 negatively regulates T-cell receptor
CC       signaling. {ECO:0000250, ECO:0000269|PubMed:10196263,
CC       ECO:0000269|PubMed:15537652, ECO:0000269|PubMed:1699196,
CC       ECO:0000269|PubMed:22080863}.
CC   -!- PTM: Palmitoylation at Cys-3 and Cys-6 regulates subcellular
CC       location. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14676; AAA36615.1; -; mRNA.
DR   EMBL; M14333; AAC08285.1; -; mRNA.
DR   EMBL; S74774; AAB33113.2; -; mRNA.
DR   EMBL; AB451293; BAG70107.1; -; mRNA.
DR   EMBL; AB451426; BAG70240.1; -; mRNA.
DR   EMBL; Z97989; CAI22300.1; -; Genomic_DNA.
DR   EMBL; Z97989; CAI22301.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48278.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48279.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48281.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48282.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48283.1; -; Genomic_DNA.
DR   EMBL; BC032496; AAH32496.1; -; mRNA.
DR   CCDS; CCDS5094.1; -. [P06241-1]
DR   CCDS; CCDS5095.1; -. [P06241-2]
DR   CCDS; CCDS5096.1; -. [P06241-3]
DR   PIR; A24314; TVHUSY.
DR   RefSeq; NP_002028.1; NM_002037.5. [P06241-1]
DR   RefSeq; NP_694592.1; NM_153047.3. [P06241-2]
DR   RefSeq; NP_694593.1; NM_153048.3. [P06241-3]
DR   RefSeq; XP_005266947.1; XM_005266890.3. [P06241-2]
DR   RefSeq; XP_005266949.1; XM_005266892.3. [P06241-3]
DR   RefSeq; XP_016866139.1; XM_017010650.1. [P06241-1]
DR   RefSeq; XP_016866140.1; XM_017010651.1. [P06241-1]
DR   RefSeq; XP_016866141.1; XM_017010652.1. [P06241-1]
DR   RefSeq; XP_016866142.1; XM_017010653.1. [P06241-1]
DR   RefSeq; XP_016866143.1; XM_017010654.1. [P06241-1]
DR   UniGene; Hs.390567; -.
DR   UniGene; Hs.664520; -.
DR   PDB; 1A0N; NMR; -; B=80-148.
DR   PDB; 1AOT; NMR; -; F=143-248.
DR   PDB; 1AOU; NMR; -; F=143-248.
DR   PDB; 1AVZ; X-ray; 3.00 A; C=85-141.
DR   PDB; 1AZG; NMR; -; B=82-148.
DR   PDB; 1EFN; X-ray; 2.50 A; A/C=86-143.
DR   PDB; 1FYN; X-ray; 2.30 A; A=81-142.
DR   PDB; 1G83; X-ray; 2.60 A; A/B=82-246.
DR   PDB; 1M27; X-ray; 2.50 A; C=84-144.
DR   PDB; 1NYF; NMR; -; A=82-148.
DR   PDB; 1NYG; NMR; -; A=82-148.
DR   PDB; 1SHF; X-ray; 1.90 A; A/B=84-142.
DR   PDB; 1ZBJ; NMR; -; A=84-142.
DR   PDB; 2DQ7; X-ray; 2.80 A; X=261-537.
DR   PDB; 2MQI; NMR; -; A=148-248.
DR   PDB; 2MRJ; NMR; -; A=148-248.
DR   PDB; 2MRK; NMR; -; A=149-248, B=528-537.
DR   PDB; 3H0F; X-ray; 2.61 A; A=73-142.
DR   PDB; 3H0H; X-ray; 1.76 A; A=73-142.
DR   PDB; 3H0I; X-ray; 2.20 A; A/B=73-142.
DR   PDB; 3UA6; X-ray; 1.85 A; A/B=81-143.
DR   PDB; 3UA7; X-ray; 1.50 A; A/B/C/D=81-143.
DR   PDB; 4D8D; X-ray; 2.52 A; A/C=84-141.
DR   PDB; 4EIK; X-ray; 1.60 A; A=81-143.
DR   PDB; 4U17; X-ray; 1.99 A; A/B/C=148-248.
DR   PDB; 4U1P; X-ray; 1.40 A; A=148-248.
DR   PDB; 4ZNX; X-ray; 2.10 A; A/B/C/D=84-141.
DR   PDBsum; 1A0N; -.
DR   PDBsum; 1AOT; -.
DR   PDBsum; 1AOU; -.
DR   PDBsum; 1AVZ; -.
DR   PDBsum; 1AZG; -.
DR   PDBsum; 1EFN; -.
DR   PDBsum; 1FYN; -.
DR   PDBsum; 1G83; -.
DR   PDBsum; 1M27; -.
DR   PDBsum; 1NYF; -.
DR   PDBsum; 1NYG; -.
DR   PDBsum; 1SHF; -.
DR   PDBsum; 1ZBJ; -.
DR   PDBsum; 2DQ7; -.
DR   PDBsum; 2MQI; -.
DR   PDBsum; 2MRJ; -.
DR   PDBsum; 2MRK; -.
DR   PDBsum; 3H0F; -.
DR   PDBsum; 3H0H; -.
DR   PDBsum; 3H0I; -.
DR   PDBsum; 3UA6; -.
DR   PDBsum; 3UA7; -.
DR   PDBsum; 4D8D; -.
DR   PDBsum; 4EIK; -.
DR   PDBsum; 4U17; -.
DR   PDBsum; 4U1P; -.
DR   PDBsum; 4ZNX; -.
DR   ProteinModelPortal; P06241; -.
DR   SMR; P06241; -.
DR   BioGrid; 108810; 186.
DR   DIP; DIP-33876N; -.
DR   IntAct; P06241; 240.
DR   MINT; MINT-93594; -.
DR   STRING; 9606.ENSP00000346671; -.
DR   BindingDB; P06241; -.
DR   ChEMBL; CHEMBL1841; -.
DR   DrugBank; DB02078; 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane.
DR   DrugBank; DB01254; Dasatinib.
DR   GuidetoPHARMACOLOGY; 2026; -.
DR   iPTMnet; P06241; -.
DR   PhosphoSitePlus; P06241; -.
DR   SwissPalm; P06241; -.
DR   BioMuta; FYN; -.
DR   DMDM; 125370; -.
DR   EPD; P06241; -.
DR   MaxQB; P06241; -.
DR   PaxDb; P06241; -.
DR   PeptideAtlas; P06241; -.
DR   PRIDE; P06241; -.
DR   DNASU; 2534; -.
DR   Ensembl; ENST00000229471; ENSP00000229471; ENSG00000010810. [P06241-3]
DR   Ensembl; ENST00000354650; ENSP00000346671; ENSG00000010810. [P06241-1]
DR   Ensembl; ENST00000368667; ENSP00000357656; ENSG00000010810. [P06241-1]
DR   Ensembl; ENST00000368678; ENSP00000357667; ENSG00000010810. [P06241-2]
DR   Ensembl; ENST00000368682; ENSP00000357671; ENSG00000010810. [P06241-2]
DR   Ensembl; ENST00000538466; ENSP00000440646; ENSG00000010810. [P06241-2]
DR   GeneID; 2534; -.
DR   KEGG; hsa:2534; -.
DR   UCSC; uc003pvh.3; human. [P06241-1]
DR   CTD; 2534; -.
DR   DisGeNET; 2534; -.
DR   GeneCards; FYN; -.
DR   HGNC; HGNC:4037; FYN.
DR   HPA; CAB005034; -.
DR   HPA; CAB018387; -.
DR   HPA; HPA023887; -.
DR   HPA; HPA063770; -.
DR   MIM; 137025; gene.
DR   neXtProt; NX_P06241; -.
DR   OpenTargets; ENSG00000010810; -.
DR   PharmGKB; PA28454; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P06241; -.
DR   KO; K05703; -.
DR   OMA; SHNSGYR; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P06241; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-164944; Nef and signal transduction.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-2029481; FCGR activation.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-373753; Nephrin interactions.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-389356; CD28 co-stimulation.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-418886; Netrin mediated repulsion signals.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5621480; Dectin-2 family.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-75892; Platelet Adhesion to exposed collagen.
DR   Reactome; R-HSA-8866376; Reelin signalling pathway.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P06241; -.
DR   SIGNOR; P06241; -.
DR   ChiTaRS; FYN; human.
DR   EvolutionaryTrace; P06241; -.
DR   GeneWiki; FYN; -.
DR   GenomeRNAi; 2534; -.
DR   PMAP-CutDB; P06241; -.
DR   PRO; PR:P06241; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000010810; -.
DR   CleanEx; HS_FYN; -.
DR   ExpressionAtlas; P06241; baseline and differential.
DR   Genevisible; P06241; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005768; C:endosome; IDA:HGNC.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0045121; C:membrane raft; IMP:ARUK-UCL.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042609; F:CD4 receptor binding; IEA:Ensembl.
DR   GO; GO:0042610; F:CD8 receptor binding; IEA:Ensembl.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0001664; F:G-protein coupled receptor binding; IEA:Ensembl.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044325; F:ion channel binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0051428; F:peptide hormone receptor binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:UniProtKB.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004871; F:signal transducer activity; IEA:Ensembl.
DR   GO; GO:0042608; F:T cell receptor binding; IEA:Ensembl.
DR   GO; GO:0015631; F:tubulin binding; IEA:Ensembl.
DR   GO; GO:0050798; P:activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0006816; P:calcium ion transport; NAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0048813; P:dendrite morphogenesis; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0007612; P:learning; TAS:ProtInc.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:1902951; P:negative regulation of dendritic spine maintenance; IEA:Ensembl.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IEA:Ensembl.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; IEA:Ensembl.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:1905664; P:regulation of calcium ion import across plasma membrane; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:Ensembl.
DR   GO; GO:0050690; P:regulation of defense response to virus by virus; TAS:Reactome.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:1904645; P:response to beta-amyloid; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042110; P:T cell activation; IBA:GO_Central.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Cell membrane; Complete proteome; Cytoplasm; Developmental protein;
KW   Host-virus interaction; Immunity; Kinase; Lipoprotein; Manganese;
KW   Membrane; Metal-binding; Myristate; Nucleotide-binding; Nucleus;
KW   Palmitate; Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Reference proteome; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    537       Tyrosine-protein kinase Fyn.
FT                                /FTId=PRO_0000088099.
FT   DOMAIN       82    143       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      149    246       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      271    524       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     277    285       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    390    390       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     299    299       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      12     12       Phosphothreonine; by PKC.
FT                                {ECO:0000269|PubMed:15537652}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     185    185       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P39688}.
FT   MOD_RES     420    420       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P39688}.
FT   MOD_RES     531    531       Phosphotyrosine; by CSK.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:1699196}.
FT   LIPID         2      2       N-myristoyl glycine.
FT                                {ECO:0000269|PubMed:1699196}.
FT   LIPID         3      3       S-palmitoyl cysteine. {ECO:0000250}.
FT   LIPID         6      6       S-palmitoyl cysteine. {ECO:0000250}.
FT   VAR_SEQ     233    287       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_024108.
FT   VAR_SEQ     234    287       RAAGLCCRLVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLI
FT                                KRLGNGQFGEVWM -> KADGLCFNLTVIASSCTPQTSGLA
FT                                KDAWEVARRSLCLEKKLGQGCFAEVWL (in isoform
FT                                2). {ECO:0000303|PubMed:7822789}.
FT                                /FTId=VSP_024110.
FT   VARIANT     243    243       V -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041704.
FT   VARIANT     410    410       G -> R (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041705.
FT   VARIANT     445    445       I -> F (in dbSNP:rs1801121).
FT                                /FTId=VAR_014661.
FT   VARIANT     506    506       D -> E (in dbSNP:rs28763975).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041706.
FT   CONFLICT    184    184       A -> S (in Ref. 1; AAA36615).
FT                                {ECO:0000305}.
FT   CONFLICT    437    437       A -> R (in Ref. 1; AAA36615 and 3;
FT                                AAB33113). {ECO:0000305}.
FT   STRAND       87     91       {ECO:0000244|PDB:3UA7}.
FT   STRAND       96    100       {ECO:0000244|PDB:3UA6}.
FT   STRAND      108    113       {ECO:0000244|PDB:3UA7}.
FT   STRAND      115    124       {ECO:0000244|PDB:3UA7}.
FT   TURN        125    127       {ECO:0000244|PDB:3UA7}.
FT   STRAND      130    134       {ECO:0000244|PDB:3UA7}.
FT   HELIX       135    137       {ECO:0000244|PDB:3UA7}.
FT   STRAND      138    141       {ECO:0000244|PDB:3UA7}.
FT   HELIX       144    146       {ECO:0000244|PDB:1G83}.
FT   STRAND      147    150       {ECO:0000244|PDB:1G83}.
FT   HELIX       156    163       {ECO:0000244|PDB:4U1P}.
FT   TURN        165    167       {ECO:0000244|PDB:1AOT}.
FT   STRAND      172    177       {ECO:0000244|PDB:4U1P}.
FT   STRAND      179    181       {ECO:0000244|PDB:4U1P}.
FT   STRAND      185    193       {ECO:0000244|PDB:4U1P}.
FT   TURN        194    196       {ECO:0000244|PDB:4U1P}.
FT   STRAND      197    207       {ECO:0000244|PDB:4U1P}.
FT   TURN        209    211       {ECO:0000244|PDB:1AOT}.
FT   STRAND      213    216       {ECO:0000244|PDB:4U1P}.
FT   STRAND      219    223       {ECO:0000244|PDB:4U1P}.
FT   HELIX       224    233       {ECO:0000244|PDB:4U1P}.
FT   STRAND      238    240       {ECO:0000244|PDB:4U1P}.
FT   STRAND      263    265       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       268    270       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      271    278       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      285    290       {ECO:0000244|PDB:2DQ7}.
FT   TURN        291    293       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      294    299       {ECO:0000244|PDB:2DQ7}.
FT   TURN        303    305       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       308    318       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      329    333       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      335    337       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      339    343       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       350    354       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      355    357       {ECO:0000244|PDB:2DQ7}.
FT   TURN        358    360       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       364    383       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       393    395       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      396    399       {ECO:0000244|PDB:2DQ7}.
FT   TURN        400    402       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      403    406       {ECO:0000244|PDB:2DQ7}.
FT   STRAND      416    418       {ECO:0000244|PDB:2DQ7}.
FT   TURN        430    432       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       435    438       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       445    460       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       472    481       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       496    502       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       507    509       {ECO:0000244|PDB:2DQ7}.
FT   HELIX       513    521       {ECO:0000244|PDB:2DQ7}.
SQ   SEQUENCE   537 AA;  60762 MW;  4A1E443A4B5A0977 CRC64;
     MGCVQCKDKE ATKLTEERDG SLNQSSGYRY GTDPTPQHYP SFGVTSIPNY NNFHAAGGQG
     LTVFGGVNSS SHTGTLRTRG GTGVTLFVAL YDYEARTEDD LSFHKGEKFQ ILNSSEGDWW
     EARSLTTGET GYIPSNYVAP VDSIQAEEWY FGKLGRKDAE RQLLSFGNPR GTFLIRESET
     TKGAYSLSIR DWDDMKGDHV KHYKIRKLDN GGYYITTRAQ FETLQQLVQH YSERAAGLCC
     RLVVPCHKGM PRLTDLSVKT KDVWEIPRES LQLIKRLGNG QFGEVWMGTW NGNTKVAIKT
     LKPGTMSPES FLEEAQIMKK LKHDKLVQLY AVVSEEPIYI VTEYMNKGSL LDFLKDGEGR
     ALKLPNLVDM AAQVAAGMAY IERMNYIHRD LRSANILVGN GLICKIADFG LARLIEDNEY
     TARQGAKFPI KWTAPEAALY GRFTIKSDVW SFGILLTELV TKGRVPYPGM NNREVLEQVE
     RGYRMPCPQD CPISLHELMI HCWKKDPEER PTFEYLQSFL EDYFTATEPQ YQPGENL
//
